Replies to post #147115 on Biotech Values

[iwfal]

the new Phase 1b formulation that's expected to report out at ASH is significantly more potent than the prior version

Question: how do they measure potency? IC50? ... ? Way too many companies tout "My IC50 (or a similar measure) is better than the competitors" when IC50 is, at best, a very poor proxy for efficacy vs toxicity (E vs T) - which is the primary metric of importance (specificity is probably a substantially better proxy for E vs T, but, of course, is much harder to measure.)

Just a pet peeve for the night! -g-